A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung CancerHARMONi-3

Brief Summary

Type:
Lung Cancers

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT05899608

Study #:
STUDY00161223

Start Date:
May 21, 2025

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05899608

View Complete Trial Details & Eligibility at ClinicalTrials.gov